Multicell Technologies

Multicell Technologies EBITDA Margin

The EBITDA Margin of Multicell Technologies (MCET) as of Oct 21, 2026 is -1,466.13 %.

EBITDA Margin

-1,466.13 %

Last updated:

EBITDA Margin of Multicell Technologies is 2014 -1,466.13 % . EBITDA Margin of Multicell Technologies was 2013 - . It decreases by % lower compared to the previous year.

The Multicell Technologies EBITDA Margin history

The Multicell Technologies EBITDA Margin history
YEAREBITDA MarginYoY
-1,466.13 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Multicell Technologies Stock analysis

What does Multicell Technologies do? Multicell Technologies Inc is a US-American company specialized in the development and production of innovative products in the field of biomedical and biotechnological research. The company was founded in 1987 by a team of scientists and has held a leading position in the industry ever since. They develop technologies for the isolation and artificial reproduction of cell cultures, collaborate with leading scientists and research institutions to develop new methods and products for fighting diseases such as cancer and cardiovascular diseases, and offer a wide range of products for biomedical and biotechnological research, including cell culture systems, antibody products, and specialized analysis tools. They also work on the production of cell lines and cultures and develop active therapeutics, including a program for developing a new therapeutic for multiple sclerosis. Additionally, they have a diagnostics business and have developed a special platform for DNA sequencing. Overall, Multicell Technologies Inc is known for its close collaboration with the scientific community and its dedication to developing innovative products for the medical field. Multicell Technologies is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Multicell Technologies stock

EBITDA Margin of Multicell Technologies is -1,466.13 % in 2014.

On Eulerpool you can find the complete historical development of EBITDA Margin Multicell Technologies since 2006 – with annual values, charts, and detailed analysis.

EBITDA Margin shows what percentage of revenue converts to EBITDA. It normalizes for depreciation and capital structure differences.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBITDA Margin's Multicell Technologies with sector peers and the industry average to assess whether it is attractive.

To evaluate EBITDA Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBITDA Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Multicell Technologies

All Key Metrics — Multicell Technologies